Literature DB >> 14527910

Telomerase inhibition using azidothymidine in the HT-29 colon cancer cell line.

Tommy Brown1, Elin Sigurdson, Andre Rogatko, Dominique Broccoli.   

Abstract

BACKGROUND: We investigated the effects of telomerase inhibition by using the reverse transcriptase inhibitor azidothymidine (AZT) in the human colorectal cancer cell line HT-29 in the presence and absence of 5-fluorouracil (5-FU).
METHODS: HT-29 cells were cultured in the presence of AZT. Telomerase activity was measured by using the telomerase repeat amplification protocol. Telomere length was determined by Southern analysis. The colorimetric microtiter assay was performed to determine the cytotoxic effects of AZT, alone and in combination with 5-FU.
RESULTS: The presence of 3'-azido-3'-deoxythymidine triphosphate (AZT-TP) effectively inhibited telomerase extracted from HT-29 cells. HT-29 cells cultured with 125 microM of AZT underwent fewer total population doublings over 91 days. Southern analysis revealed that telomere attrition occurred within this period. Exposure to 125 microM of AZT resulted in slightly reduced viability (10%) of HT-29 cells. However, the presence of AZT increased 5-FU cytotoxicity, suggesting that the effects of these two drugs are synergistic.
CONCLUSIONS: The data are consistent with telomerase inhibition having growth-inhibitory effects in addition to those predicted to accompany loss of telomere function. Further studies using specific small-molecule inhibitors will confirm whether the growth-inhibitory and 5-FU-sensitivity effects seen here are a direct result of telomerase inhibition.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14527910     DOI: 10.1245/aso.2003.03.032

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  17 in total

1.  Targeting human telomerase for cancer therapeutics.

Authors:  Lionel Guittat; Patrizia Alberti; Dennis Gomez; Anne De Cian; Gaëlle Pennarun; Thibault Lemarteleur; Chafke Belmokhtar; Rajaa Paterski; Hamid Morjani; Chantal Trentesaux; Eliane Mandine; François Boussin; Patrick Mailliet; Laurent Lacroix; Jean-François Riou; Jean-Louis Mergny
Journal:  Cytotechnology       Date:  2004-06       Impact factor: 2.058

Review 2.  Telomerase and the endocrine system.

Authors:  Furio Pacini; Silvia Cantara; Marco Capezzone; Stefania Marchisotta
Journal:  Nat Rev Endocrinol       Date:  2011-03-29       Impact factor: 43.330

3.  Leukocyte Telomere Length at Birth and During the Early Life of Children Exposed to but Uninfected With HIV After In Utero Exposure to Antiretrovirals.

Authors:  Abhinav Ajaykumar; Hugo Soudeyns; Fatima Kakkar; Jason Brophy; Ari Bitnun; Ariane Alimenti; Arianne Y K Albert; Deborah M Money; Hélène C F Côté
Journal:  J Infect Dis       Date:  2018-02-14       Impact factor: 5.226

Review 4.  HIV infection, aging, and immune function: implications for cancer risk and prevention.

Authors:  Robert Dubrow; Michael J Silverberg; Lesley S Park; Kristina Crothers; Amy C Justice
Journal:  Curr Opin Oncol       Date:  2012-09       Impact factor: 3.645

5.  Combination of resveratrol and BIBR1532 inhibits proliferation of colon cancer cells by repressing expression of LncRNAs.

Authors:  Bakiye Goker Bagca; Hasan Onur Caglar; Selin Cesmeli; Neslihan Pinar Ozates; Cumhur Gunduz; Cigir Biray Avci
Journal:  Med Oncol       Date:  2021-11-15       Impact factor: 3.064

Review 6.  Telomerase and its potential for therapeutic intervention.

Authors:  P Phatak; A M Burger
Journal:  Br J Pharmacol       Date:  2007-07-02       Impact factor: 8.739

7.  AZT as a telomerase inhibitor.

Authors:  Daniel E Gomez; Romina G Armando; Daniel F Alonso
Journal:  Front Oncol       Date:  2012-09-06       Impact factor: 6.244

8.  In vitro and ex vivo inhibition of human telomerase by anti-HIV nucleoside reverse transcriptase inhibitors (NRTIs) but not by non-NRTIs.

Authors:  Kyle R Hukezalie; Naresh R Thumati; Hélène C F Côté; Judy M Y Wong
Journal:  PLoS One       Date:  2012-11-15       Impact factor: 3.240

9.  Azidothymidine "Clicked" into 1,2,3-Triazoles: First Report on Carbonic Anhydrase-Telomerase Dual-Hybrid Inhibitors.

Authors:  Emanuela Berrino; Andrea Angeli; Dmitry D Zhdanov; Anna P Kiryukhina; Andrea Milaneschi; Alessandro De Luca; Murat Bozdag; Simone Carradori; Silvia Selleri; Gianluca Bartolucci; Thomas S Peat; Marta Ferraroni; Claudiu T Supuran; Fabrizio Carta
Journal:  J Med Chem       Date:  2020-06-10       Impact factor: 7.446

10.  Effect of 3`-Azido-3`-Deoxythymidine (AZT) on Telomerase Activity and Proliferation of HO-8910 Cell Line of Ovarian Cancer.

Authors:  Hongmei Li; Tianbao Song; Weizhong Xu; Yuecheng Yu; Xiaoyan Xin; Du Hui
Journal:  Int J Biomed Sci       Date:  2006-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.